535 THE EFFECTS OF RUANGULI IN THE TREATMENT OF EXPERIMENTAL OSTEOARTHRITIS OF THE KNEE IN RABBITS  by Jian, P. et al.
Osteoarthritis and Cartilage Vol. 17, Supplement 1 S287
sented only 18% of total NSAIDs, its cost represented the 64%
of all NSAIDs. Glucosamine Sulfate represented the 60% of the
spending on SYSADOAs. Total pharmacological cost per patient
per year was 151,60€.
Conclusions: Knee osteoarthritis is a major cause of utilisation of
health care resources and sick leave. The total pharmacological
cost per patient per year was 151,60€. This amount is less than
needed to treat most chronic rheumatic diseases, and represents
a small fraction of the cost for the management of KOA.
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Purpose: The objective of the present study was to investigate
the mRNA expression level of α-actin, MHC (myosin heavy chain)
isoforms (MHCI, IIa, IId/x, IIb), ADAMTS5 and Aggrecan in rabbit
osteoarthritis model. To explore the effects of Ruanguli (A kind
of Chinese herbal medicine compound recipe) in the treatment of
knee osteoarthritis.
Methods: 36 adult, female New Zealand white rabbits were ran-
domized in three groups, including sham control group, model
control group, treatment group (RuanGuLi 2mg/day, 4 weeks). Os-
teoarthritis of the knee was induced surgically in 28 rabbits (model
control group, treatment group). The other animals wee sham op-
erated. One week after operation, interfering measures were taken
into practice and lasted for 4 weeks. Animals were euthanized at
5 weeks postoperatively. RT-PCR was used to assess the mRNA
expression level of α-actin, MHC isoforms in quadriceps femoris,
Aggrecan and ADAMTS5 in knee cartilage. Mankin score was
used to assess cartilage degeneration in the knee.
Results: The result of Mankin score suggested that there was
signiﬁcant difference between model control group and treatment
group, Ruanguli treatment led to a signiﬁcant reduction in articular
cartilage degeneration. The results of RT-PCR suggested that the
expression level of MHCIIa mRNA,MHCIId/x mRNA and α-actin
mRNA in model group was signiﬁcantly lower than that in sham
control group. Ruanguli treatment signiﬁcantly increased the level
of MHCIIa,MHCIIb and α-actin mRNA when compared to model
control group. Ruanguli treatment led to a signiﬁcant increase in
the expression level of Aggrecan mRNA expression and reduction
in ADAMTS5 mRNA expression in articular cartilage.
Conclusions: In OA animals, the level of α-actin and MHC isforms
mRNA was lower compared with normal animals. Ruanguli sig-
niﬁcantly increased α-actin, some MHC and Aggrecan expression
as well as inhibited the expression of ADAMTS5 and reduced
cartilage degeneration in knee.
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Purpose: The pathogenesis of primary osteoarthritis involves an
imbalance between anabolic and catabolic pathways by chondro-
cytes. Expression of pro-inﬂammatory cytokines and matrix metal-
loproteinases, chondrocyte hypertrophy and apoptosis participate
in the pathogenesis of osteoarthritis. Chondroitin sulfate (CS) is
an important structural component of cartilage and is approved as
a symptomatic slow-acting drug for osteoarthritis (SYSADOA) in
Europe and other countries. Indeed, numerous studies showed the
good tolerance and its clinical beneﬁts to decrease pain, to improve
functional disability and to reduce non-steroidal anti-inﬂammatory
drug (NSAID) or acetaminophen consumption. However, mecha-
nisms of action in vivo and in vitro are unknown.The goal of the
study was to explore the effects of bovine CS on two main features
of osteoarthritis: proteolysis and chondrocyte apoptosis.
Methods: To address these questions, we submitted immortalized
human chondrocyte cell line C-20/A4 to bovine CS. Chondrocytes
were treated or not with 2 ng/ml human interleukin 1 beta (IL-
1 beta) alone or with 500 μg/ml of bovine CS for 20 hours in
DMEM culture medium free from foetal bovine serum. Expres-
sion of collagenases MMP-1, MMP-13 and their speciﬁc inhibitor
TIMP-1 was checked by ELISA assay in the culture medium.
ADAMTS-5 expression (a disintegrin and metalloproteinase with
thrombospondin motifs) was analyzed by western blot. Cell viabil-
ity was performed by trypan blue, cell cycle analysis and apoptosis
level were investigated by ﬂow cytometry.
Results: Treatment of chondrocytes by 500 μg/ml CS protected
the cells from death induced by 6 days incubation with 2 ng/mI
IL-1β: upon CS and IL-1, 75% cells were alive compare to 50%
without CS. Cell cycle analysis by FACS showed a signiﬁcant
decrease by CS of apoptosis in IL1-treated cells: 2% apoptotic
cells with versus 15% without). Moreover, CS decreased the IL-1
mediated expression of ADAMTS-5 contrary to that of MMP-1,
MMP-13 and TIMP-1.
Conclusions: The proinﬂammatory cytokine interleukin-1 beta
participates in the pathogenesis of cartilage damage in osteoarthri-
tis. In this study we provided experimental evidence that bovine
CS decreases ADAMTS-5 expression and protects from apop-
tosis of human chondrocyte cell line stimulated by IL-1β. These
results emphasize the potential beneﬁcial effect of bovine CS in
osteoarthritis.
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Purpose: Today’s total hip arthroplasty (THA) patients, who are
